Corticotropin-releasing factor inhibits luteinizing hormone-stimulated P450c17 gene expression and androgen production by isolated thecal cells of human ovarian follicles.
Recently, we reported that the thecal compartment of the human ovary contains a CRF system replete with gene expression and protein for corticotropin-releasing factor (CRF), CRF-Receptor 1 (CRF-R1), and the blood-derived high affinity CRF binding protein (CRF-BP). Granulosa cells are devoid of the CRF system. The parallel increases in intensity of CRF, CRF-R1, and 17 alpha-hydroxylase messenger ribonucleic acid (mRNA) and proteins in thecal cells with follicular maturation suggest that the intraovarian CRF system may play an autocrine role regulating androgen biosynthesis, with a downstream effect on estrogen production by granulosa cells. The functionality of the ovarian CRF system may be conditioned by the relative presence of plasma-derived CRF-BP by virtue of its localization of protein, but not transcript in thecal cells and its ability to compete with CRF for the CRF receptor. To further these findings, in the present study we have examined the effect of CRF on LH-stimulated 17 alpha-hydroxylase (P450c17) gene expression and androgen production by isolated thecal cells from human ovarian follicles (11-13 mm). During the 48-h culture, addition of LH (10 ng/mL) to the medium increased by 5- and 6-fold dehydroepiandrosterone and androstenedione production by thecal cells. Remarkably, the LH-stimulated, but not basal, androgen production was inhibited by CRF in a time- and dose-dependent manner. The half-maximal (ID50) effect dose of CRF occurred at 5 x 10(-8) mol/L, and at a maximal concentration of 10(-6) mol/L, CRF completely inhibited LH-stimulated androgen production. This inhibitory effect of CRF became evident at 12 h (45%), and by 24 h the effect was more pronounced, with a 70% reduction from baseline. As determined by Northern analyses, CRF dose dependently decreased LH-stimulated P450c17 mRNA levels, with a maximal inhibition of 85% P450c17 gene expression at a CRF concentration of 10(-6) mol/L. With the addition of 10(-6) mol/L of the antagonist alpha-helical CRF-(9-41), the inhibitory effect of CRF was partially reversed for both P450c17 mRNA (75%) and androgen production (50%), indicating the CRF-R1-mediated event. In conclusion, the present study demonstrated a potent inhibitory effect of CRF on LH-stimulated dehydroepiandrosterone and androstenedione production that appears to be mediated through the reduction of P450c17 gene expression. Thus, the ovarian CRF system may function as autocrine regulators for androgen biosynthesis in the thecal cell compartment to maintain optimal substrate for estrogen biosynthesis by granulosa cells. Further studies to define the role of CRF-BP in the endocrine modulation of the intraovarian CRF system are needed.
Erden
H F
HF
Department of Reproductive Medicine, University of California-San Diego, La Jolla 92093-0633, USA.
Zwain
I H
IH
Asakura
H
H
Yen
S S
SS
D000328:Adult; D000728:Androgens / Q000096:biosynthesis*; D000735:Androstenedione / Q000096:biosynthesis; D015152:Blotting, Northern; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D003470:Culture Media; D003687:Dehydroepiandrosterone / Q000096:biosynthesis; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D007986:Luteinizing Hormone / Q000494:pharmacology*; D012333:RNA, Messenger / Q000378:metabolism; D013254:Steroid 17-alpha-Hydroxylase / Q000235:genetics* / Q000378:metabolism; D013799:Theca Cells / Q000187:drug effects / Q000201:enzymology*
D000728:Androgens; D003470:Culture Media; D012333:RNA, Messenger; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D007986:Luteinizing Hormone; D003346:Corticotropin-Releasing Hormone; D013254:Steroid 17-alpha-Hydroxylase